Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma (DLCL04)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00499018 |
Recruitment Status : Unknown
Verified February 2011 by Fondazione Italiana Linfomi - ETS.
Recruitment status was: Active, not recruiting
First Posted : July 11, 2007
Last Update Posted : February 15, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to define an improvement in patients randomized in four different arms:
Arm 1: R-MegaCHOP14x4 + R-MAD + MAD + BEAM + ASCT; Arm 1BIS: R-CHOP14x4 + R-MAD + MAD + BEAM + ASCT; Arm 2: R-MegaCHOP14x4 + R-MegaCHOP14x2; Arm 2BIS: R-CHOP14x4 + R-CHOP14x4; Which are different in dose dense chemotherapy + Rituximab with or without intensified high dose chemoimmunotherapy and support of peripheral autologous stem cells.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diffuse Large B-Cell Lymphoma IPI≥2 | Drug: Rituximab Drug: Ciclofosfamide Drug: Doxorubicina Drug: Vincristina Drug: Prednisone Drug: Pegfilgrastim Drug: Mitoxantrone Drug: ARA-C Drug: Lenograstim Drug: BCNU Drug: VP-16 Procedure: ASCT | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 399 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. |
Study Start Date : | January 2006 |
Estimated Primary Completion Date : | June 2011 |
Estimated Study Completion Date : | September 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: 1
R-MegaCHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
|
Drug: Rituximab
375 mg/m2 day 1 Drug: Ciclofosfamide 1200 mg/m2 day 1 Drug: Doxorubicina 70 mg/m2 day 1 Drug: Vincristina 1,4 mg/m2 (max 2 mg) day 1 Drug: Prednisone 100 mg day g 1-5 Drug: Pegfilgrastim 6 mg day +1 Drug: Mitoxantrone 8 mg/m2/days 1-3 Drug: ARA-C 2000 mg/m2/12h day 1 - 3 Drug: Lenograstim 5 μg/Kg/days +2 Drug: BCNU 300 mg/m2 day -7 Drug: ARA-C 200 mg/m2/12 days -6,-5,-4,-3 Drug: VP-16 100 mg/m2/12h days -6,-5,-4,-3 Procedure: ASCT PBSC Reinfusion |
Experimental: 1 BIS
R-CHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
|
Drug: Rituximab
375 mg/m2 day 1 Drug: Vincristina 1,4 mg/m2 (max 2 mg) day 1 Drug: Prednisone 100 mg day g 1-5 Drug: Pegfilgrastim 6 mg day +1 Drug: Lenograstim 5 μg/Kg/days +2 Drug: BCNU 300 mg/m2 day -7 Drug: ARA-C 200 mg/m2/12 days -6,-5,-4,-3 Drug: VP-16 100 mg/m2/12h days -6,-5,-4,-3 Procedure: ASCT PBSC Reinfusion Drug: Ciclofosfamide 750 mg/m2 day 1 Drug: Doxorubicina 50 mg/m2 day 1 Drug: Vincristina 1,4 mg/m2 (max 2 mg) day 1 |
Experimental: 2
R-MegaCHOP14 x 4 Restaging + R-MegaCHOP x 2
|
Drug: Rituximab
375 mg/m2 day 1 Drug: Ciclofosfamide 1200 mg/m2 day 1 Drug: Doxorubicina 70 mg/m2 day 1 Drug: Vincristina 1,4 mg/m2 (max 2 mg) day 1 Drug: Prednisone 100 mg day g 1-5 Drug: Pegfilgrastim 6 mg day +1 Drug: Mitoxantrone 8 mg/m2/days 1-3 Drug: ARA-C 2000 mg/m2/12h day 1 - 3 |
Experimental: 2 BIS
R-CHOP14 x 4 Restaging + R-CHOP14 x 4
|
Drug: Rituximab
375 mg/m2 day 1 Drug: Vincristina 1,4 mg/m2 (max 2 mg) day 1 Drug: Prednisone 100 mg day g 1-5 Drug: Ciclofosfamide 750 mg/m2 day 1 Drug: Doxorubicina 50 mg/m2 day 1 Drug: Vincristina 1,4 mg/m2 (max 2 mg) day 1 |
- To evaluate the activity of arms "R-MegaCHOP14/R-CHOP14 + R-MAD+BEAM and ASCT" and "R-MegaCHOP14/R-CHOP14" in terms of 2-years Failure Free Survival (FFS). [ Time Frame: 2 years ]
- To evaluate the activity of arms "R-MegaCHOP14/R-CHOP14 + R-MAD+BEAM and ASCT" and "R-MegaCHOP14/R-CHOP14" in terms of 3-years Overall Survival (OS). [ Time Frame: 3 years ]
- To evaluate the efficacy of two different dose-dense + Rituximab chemotherapy regimens in term of 2-years Failure Free Survival (FFS). [ Time Frame: 2 years ]
- To evaluate the activity of the first four courses of two different dose dense + Rituximab chemotherapy regimens (standard dose R-CHOP14 or intensified dose R-MegaCHOP14) in terms of Overall Response Rate (ORR) and Complete Remission (RC). [ Time Frame: 2 years ]
- To evaluate the efficacy of the four different induction arms in terms of 2-years FFS (exploratory analysis). [ Time Frame: 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18-60;
- Histological confirmed diagnosis of Diffuse Large B-Cell Lymphoma CD20+ (newly diagnosis or shifted from low grade NHL and not previously treated) or of Follicular Lymphoma grade III according to REAL/WHO Classification.
- Advanced stage II, stage III and stage IV with at least two aa-IPI risk factors.
- Age-adjusted IPI 2-3.
- ECOG performance status 0-2.
- LVEF>45%, measured with echocardiography.
- Normal hepatic, renal and pulmonary functions.
- HIV, HCV and HBV negativity.
- HCV+ admitted only in histologically confirmed absence of replication marks.
- Positive serology for HBV (occult carriers: AntiHBcAg+, HbsAg-, AntiHBsAg+/-) admitted only upon negativity of weakly positive HBV-DNA test.
- Life expectancy > 3 months.
- Negative pregnancy test.
- Written Informed Consent.
Exclusion Criteria:
-
Histological diagnosis of:
- Lymphoblastic NHL
- Burkitt's Lymphoma
- CD 20 negative B-cell Lymphoma
- grade I-IIIa Follicular Lymphoma
- Mantle Cell Lymphoma
- Primary mediastinal NHL with exclusively intrathoracic localization.
- Age > 60
- Stage I disease
- Age-adjusted IPI 0-1
- ECOG-PS>3, if not related to Lymphoma
- Renal impairment (creatinine>1,2 mg/dl or creatinine clearance < 60ml/min)
- Hepatic impairment (AST/ALT or bilirubin > 2,5 times normal limit, unless due to Lymphoma)
- HIV positive patients and/or with HBV or HCV active infection(documented by HBV-DNA and HCV-RNA positive tests)
- Clinically significant secondary cardiovascular disease e.g. uncontrolled hypertension (resting diastolic blood pressure > 115 mmHG), uncontrolled multifocal cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA class III-IV
- LFEV<45%
- Severe diabetes mellitus difficult to control with adequate insulin therapy
- Severe chronic obstructive pulmonary disease with hypoxemia
- Active bacterial, viral of fungal infection requiring systemic therapy
- Concurrent thrombohemolytic disease
- HIV positivity
- HBV positivity
- Positive serology for HBV (occult carriers: AntiHBc+, HbsAg-, AntiHbs+/-) with positive HBV-DNA test
- HCV positivity in presence of replication marks (HCV+, CRP+, AST 1,5-2 times normal ranges)
- CNS localization of disease
- Prior (during last 3 years) or concurrent malignancy except adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix or early stage prostate cancer not requiring systemic therapy, or early breast cancer treated with surgery alone. Any other co.existing medical condition that would preclude study therapy administration
- Pregnancy or breast-feeding women
- Inability of the patient to give her/his informed consent
- Known hypersensitivity or anaphylactic reaction to murine antibodies or proteins
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00499018
Principal Investigator: | Umberto Vitolo, MD | S.C. Ematologia II - OSP.S. GIOV.BATTISTA MOLINETTE - TORINO (TO) - |
Responsible Party: | Umberto Vitolo, A.O. San Giovanni Battista - Molinette Torino |
ClinicalTrials.gov Identifier: | NCT00499018 |
Other Study ID Numbers: |
IIL-DLCL04 EudraCT number 2007-000275-42 |
First Posted: | July 11, 2007 Key Record Dates |
Last Update Posted: | February 15, 2011 |
Last Verified: | February 2011 |
Large B-Cell Lymphoma Rituximab Autologous Stem Cell Transplantation |
Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Cytarabine Prednisone Rituximab Mitoxantrone Cyclophosphamide |
Vincristine Doxorubicin Liposomal doxorubicin Lenograstim Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antimetabolites, Antineoplastic |